| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Anterior pituitary hormone |
Is a |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Somatomedin |
Is a |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Antidiuretic hormone |
Is a |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Panhypopituitarism - anterior and posterior |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| X-linked panhypopituitarism |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prepuberal panhypopituitarism |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Panhypopituitarism |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Pituitary dwarfism with small sella turcica |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Idiopathic panhypopituitarism |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Post-birth injury panhypopituitarism (disorder) |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Post-infarction panhypopituitarism |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Other specified panhypopituitarism |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Panhypopituitarism NOS |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hormone radioassay - pituitary |
Component |
True |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Corticotropin preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing melatonin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Human growth hormone recombinant preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hormone-induced hypopituitarism |
Causative agent (attribute) |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Corticotrophins |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Posterior pituitary hormones |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Pituitary (posterior lobe) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Somatrophic hormone (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Anterior pituitary hormone-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Somatropin (substance) |
Is a |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing somatotropin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing pituitary hormone (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Pituitary luteinizing hormone |
Is a |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Anterior pituitary extract preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing corticotropin releasing factor (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Posterior pituitary hormone |
Is a |
True |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Macroprolactin |
Is a |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing follitropin alfa (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Follitropin beta preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sermorelin-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sermorelin acetate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Corticotropin preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing melatonin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Corticotrophins |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Recombinant human follicle stimulating hormone alpha 75iu powder and solvent for injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Recombinant human follicle stimulating hormone alpha 150iu injection (pdr for recon)+diluent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Recombinant human follicle stimulating hormone beta 600iu/0.72mL cartridge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Recombinant human follicle stimulating hormone beta 300iu/0.36mL cartridge (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Recombinant human follicle stimulating hormone alpha 37.5iu injection (pdr for recon)+diluent (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Recombinant human follicle stimulating hormone beta 50iu/0.5mL injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Recombinant human follicle stimulating hormone beta 100iu/0.5mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Recombinant human follicle stimulating hormone beta 150iu/0.5mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Recombinant human follicle stimulating hormone beta 200iu/0.5mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Tetracosactrin (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| cosyntrophine 250 microgrammes/1mL pour injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Tetracosactrin 1mg/1mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 1,8 UI (0,6 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 1,2 UI (0,4 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 0,6 UI (0,2 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (rmc) 24 UI (8 mg), fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 16 UI (5,33 mg), poudre et diluant pour injection avec nécessaire de reconstitution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 12 UI (4 mg), fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 2,4 UI (0,8 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 3 UI (1 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 16 UI (5,33 mg), cartouche de poudre pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 16 UI (5,33 mg), fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (rmc) 10 UI (3,33 mg), fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (rmc) 4 UI (1,33 mg), fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 4 UI (1,33 mg), fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 36 UI (12 mg), cartouche de poudre pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 18 UI (6 mg), cartouche de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 36 UI (12 mg), cartouche de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 72 UI (24 mg), cartouche de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| sermoréline 50 microgrammes, ampoules de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 3,6 UI (1,2 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 4,2 UI (1,4 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 4,8 UI (1,6 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 5,4 UI (1,8 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (efficacité biologique relative) 6 UI (2 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (epr) 3,33 mg/mL, cartouche de 1,5 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (epr) 6,66 mg/mL, cartouche de 1,5 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| somatropine (epr) 10 mg/mL, cartouche de 1,5 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Somatropin 4mg/vial powder for injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Somatropin 8.8mg/vial powder for injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Somatropin 13.5mg/3mL injection solution 3mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Somatropin 18mg/3mL injection solution 3mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Somatropin 22.5mg/3mL injection solution 3mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Somatrophic hormone (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Somatropin(rbe) 5mg(15iu)/mL injection solution 2mL cartridge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Follitropin alfa 300iu injection solution 0.5mL prefilled pen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Follitropin alfa 450iu injection solution 0.75mL prefilled pen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Follitropin alfa 900iu injection solution 1.5mL prefilled pen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cosyntropin 25mcg/mannitol 10mg injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing somatrem (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Pituitary gonadotropin preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cosyntropin preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Human growth hormone recombinant preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Bovine growth hormone recombinant preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sometribove preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing human menopausal gonadotropin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing somatotropin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Corticotropin zinc hydroxide preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Anterior pituitary extract preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prolactin-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Corticotropin 80units/mL in gelatin injection solution 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing somatropin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Follitropin beta 300iu injection solution cartridge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]